Vice President, Program Leadership (Launch Products)
Mirum Pharmaceuticals
Summary
The VP, Program Leadership (Launch Products) is accountable for defining and driving the global strategy to maximize the long-term value of Mirum's late-stage products. The Program Leader leads a cross-functional team spanning U.S. and International Commercial, Development, Regulatory, Medical Affairs, CMC/Technical Operations, Market Access, Finance, and other functions, ensuring alignment around a single integrated product vision and strategy.
Job description
Position Summary
The VP, Program Leadership (Launch Products) is accountable for defining and driving the global strategy to maximize the long-term value of Mirum's late-stage products. The Program Leader leads a cross-functional team spanning U.S. and International Commercial, Development, Regulatory, Medical Affairs, CMC/Technical Operations, Market Access, Finance, and other functions, ensuring alignment around a single integrated product vision and strategy.
The VP, Program Leadership (Launch Products) will initially provide leadership across Mirum's commercial-stage portfolio, including LIVMARLI, ATEBRIOZ, CHOLBAM, and CTEXLI, identifying and prioritizing opportunities to maximize patient impact and product value globally.
The Program Leader operates as "Program CEO," leading product strategy and execution, influencing executive leadership, and bringing together cross-functional leaders around a shared vision.
Global Product Strategy and Value Maximization for Commercial Portfolio
- Define and execute the integrated global lifecycle strategy for assigned products, establishing the long-term vision and value-maximization plan, taking into account risks, tradeoffs, and value
- Identify and prioritize opportunities across geographies, indications, patient segments, formulations, evidence generation, regulatory pathways, and other lifecycle initiatives
- Continuously reassess product strategy based on emerging clinical data, competitive developments, market dynamics, regulatory changes, product performance, and IP considerations
- Lead the cross-functional Program Team, including representatives from U.S. and International Commercial, Development, Regulatory, Medical Affairs, CMC/Technical Operations, Market Access, Finance, Legal, and other relevant functions
- Working closely with regional commercial leaders, evaluate geographic expansion opportunities and commercialization models, including direct entry, distributors, partnerships, and licensing
- Lead the evaluation of new indications, expanded patient populations, label enhancements, combination strategies, and other development opportunities
- Drive cross-functional decision-making, ensuring key trade-offs and internal resource constraints are identified, evaluated, and resolved
- Working closely with Finance and other cross-functional leaders, rationalize, get endorsement, and manage the Program Team budget, as part of the annual long-range planning exercise
Success Criteria
- Lead through influence across senior cross-functional stakeholders and create accountability across organizational boundaries
- Balance commercial opportunity with scientific, regulatory, operational, and financial considerations, making explicit strategic choices and trade-offs
- Prioritize lifecycle opportunities and investments based on patient impact, strategic fit, value creation, probability of success, investment requirements, and organizational capacity
- Develop and communicate business cases, investment recommendations, and strategic scenarios to executive leadership and governance committees to drive timely decisions and resource allocation
- Translate complex information into clear recommendations and decisions
- Maintain a global, long-term perspective while driving near-term execution
- Represent the program and Mirum externally, with thought leaders, prospective partners, and other stakeholders
Requirements
- 15+ years of experience in the biopharmaceutical industry
- Significant experience in commercial strategy, marketing, new product planning, global commercialization, or related leadership roles
- Prior experience in rare disease and/or specialty pharmaceuticals preferred
- Demonstrated success leading global product or lifecycle strategy for marketed and/or late-stage products
- Strong commercial foundation with experience in product strategy, positioning, forecasting, market development, launch planning, competitive strategy, and long-range commercial plans
- Global mindset and ability to incorporate U.S. and international market perspectives into product strategy
- Significant experience leading senior cross-functional teams spanning Commercial, Development, Medical Affairs, Regulatory, Market Access, CMC/Technical Operations, Finance, and other functions
- Leadership through influence without direct authority
- Ability to operate as an enterprise product leader integrating commercial, clinical, regulatory, medical, technical, and financial perspectives
- Strong strategic and financial acumen including business case development, investment evaluation, product P&Ls and forecasts, and resource-allocation recommendations
- Track record of making effective decisions amid complexity, uncertainty, competing priorities, and cross-functional trade-offs
- Strong understanding of the global biopharmaceutical commercialization environment
- Demonstrated ability to influence and align senior executives and functional leaders
- Excellent executive communication skills
- Strong orientation toward patient impact and value creation
- Bachelor's degree required
- MBA or other advanced degree preferred
Company overview
Mirum Pharmaceuticals is a biopharmaceutical company dedicated to developing and commercializing transformative therapies for rare liver diseases. Founded in 2018 and headquartered in Foster City, California, the company focuses on addressing critical unmet medical needs in patients with cholestatic liver conditions. Mirum has three approved medications: LIVMARLI® (maralixibat), an IBAT inhibitor approved for cholestatic pruritus in Alagille syndrome and progressive familial intrahepatic cholestasis; CHOLBAM® (cholic acid) capsules for bile acid synthesis disorders; and CTEXLI™ (chenodiol) tablets for cerebrotendinous xanthomatosis. The company's late-stage pipeline includes volixibat for primary sclerosing cholangitis and primary biliary cholangitis, and MRM-3379 for Fragile X syndrome. Mirum operates globally with commercial access in over 30 countries and has demonstrated strong revenue growth, with 2024 net product sales reaching $336.4 million. The company is publicly traded on NASDAQ under the ticker MIRM and employs approximately 201-500 people.